Nicolazzo et al. showed that in NSCLC patients treated with the programmed cell death protein (PD-1) inhibitor nivolumab at baseline and at 3 months of treatment, the presence of CTCs and the expression of PD-L1 on their surface is associated with poor patients’ outcome. This evidence concerns the gene CD274 and non-small cell lung carcinoma.